Magnetic nanofibers for remotely triggered catalytic activity applied to the degradation of organic pollutants

This work reports on the fabrication and characterization of a novel type of electrospun magnetic nanofibers (MNFs), and their application as a magnetically-activable catalysts for degradation of organic pollutants. The magnetic stimulation capability for the catalytic action is provided by iron-manganese oxide (MnxFe2-xO4) magnetic nanoparticles (MNPs) embedded into electrospun polyacrylonitrile (PAN), which provides stability and chemical resistance. The MNPs (average size d = 40 ± 7 nm) were first obtained by a green and fast sonochemical route, and subsequently embedded into electrospun PAN nanofibers. The final MNFs showed an average diameter of 760 ± 150 nm, providing a superhydrophobic surface with contact angle (θc = 165°), as well as a considerable amount ( 50 % wt.) of embedded MNPs (Mn0.5Fe2.5O4), thermally stable up to temperatures of 330 °C. The catalytic Fe2+/3+/Mn2+/3+/4+ active centers on the MNPs of MNF’s surface could be remotely activated by alternating magnetic fields (AMF) to degrade the methyl blue (MB). Remarkable stability of the MNFs during heating under extreme pH conditions (3 80 %, after several cycles of reusing the same sample without any regeneration process. The capacity of these materials as a catalytic material with magnetic remote activation makes them appealing for those catalytic applications under conditions of darkness or restrained access, where photocatalytic reaction cannot be achieved

In vitro magnetic hyperthermia using polyphenol-coated Fe3O4¿Fe2O3 nanoparticles from Cinnamomun verum and Vanilla planifolia: The concert of green synthesis and therapeutic possibilities

We report on a new, environment-friendly synthesis route to produce Fe3O4 magnetic nanoparticles (MNPs) from extracts of the plants Vanilla planifolia and Cinnamomun verum. These aqueous plant extracts have the double function of reducing agents due to their phenolic groups, and also capping materials through the -OH bonding over the MNPs surface. The resulting MNPs have average sizes ˜10-14 nm with a core-shell Fe3O4-¿Fe2O3 structure due to surface oxidation driven by the phenolic groups through OH-covalent bonding. Saturation magnetization values of MS= 70.84 emu g-1 (C. verum) and MS = 59.45 emu g-1 (V. planifolia) are among the largest reported so far from biosynthetic samples. Electron microscopy and infrared spectroscopy data showed a thin organic layer coating the Fe3O4 @¿Fe2O3 MNPs, composed by the phenolic groups from the starting extracts of both C. verum and V. planifolia. A proof of concept for these MNPs as heating agents in magnetic hyperthermia experiments (570 kHz, 23.9 kA m-1) was performed in-vitro, showing their efficacy to induce cell death on BV2 microglial cells after 30 min at a target temperature T = 46 °C

Magnetic nanoparticles for magnetically guided therapies against neural diseases

Neurological pathologies and nerve damage are two problems of significant medical and economic impact because of the hurdles of losing nerve functionality in addition to significant mortality and morbidity, and demanding rehabilitation. There are currently a number of examples of how nanotechnology can provide new solutions for biomedical problems. Current strategies for nerve repair rely on the use of functionalized scaffolds working as nerve guidance channels to improve axonal regeneration and to direct axonal re-growth across the nerve lesion site. Since low invasiveness and high selectivity of the growth stimulation are usually conflicting requirements, new approaches are being pursued in order to overcome such limitations. Engineered magnetic nanoparticles (MNPs) have emerged from this need for noninvasive therapies for both positioning and guiding neural cells in response to an external magnetic field. Here, we review the current state of the use of MNPs for neuroprotective and magnetically guided therapies. We discuss some conceivable outcomes of current magnetically driven strategies seeking integrated platforms for regenerative action on damaged tissues

Gold-decorated magnetic nanoparticles design for hyperthermia applications and as a potential platform for their surface-functionalization

The integration of noble metal and magnetic nanoparticles with controlled structures that can couple various specific effects to the different nanocomposite in multifunctional nanosystems have been found interesting in the field of medicine. In this work, we show synthesis route to prepare small Au nanoparticles of sizes <d> = 3.9 ± 0.2 nm attached to Fe 3 O 4 nanoparticle cores (<d> = 49.2 ± 3.5 nm) in aqueous medium for potential application as a nano-heater. Remarkably, the resulted Au decorated PEI-Fe 3 O 4 (Au@PEI-Fe 3 O 4 ) nanoparticles are able to retain bulk magnetic moment M S = 82–84 Am 2 /kg Fe3O4 , with the Verwey transition observed at T V = 98 K. In addition, the in vitro cytotoxicity analysis of the nanosystem microglial BV2 cells showed high viability (>97.5%) to concentrate up to 100 µg/mL in comparison to the control samples. In vitro heating experiments on microglial BV2 cells under an ac magnetic field (H 0 = 23.87 kA/m; f = 571 kHz) yielded specific power absorption (SPA) values of SPA = 43 ± 3 and 49 ± 1 µW/cell for PEI-Fe 3 O 4 and Au@PEI-Fe 3 O 4 NPs, respectively. These similar intracellular SPA values imply that functionalization of the magnetic particles with Au did not change the heating efficiency, providing at the same time a more flexible platform for multifunctional functionalization

In silico before in vivo: How to predict the heating efficiency of magnetic nanoparticles within the intracellular space

This work aims to demonstrate the need for in silico design via numerical simulation to produce optimal Fe 3 O 4 -based magnetic nanoparticles (MNPs) for magnetic hyperthermia by minimizing the impact of intracellular environments on heating efficiency. By including the relevant magnetic parameters, such as magnetic anisotropy and dipolar interactions, into a numerical model, the heating efficiency of as prepared colloids was preserved in the intracellular environment, providing the largest in vitro specific power absorption (SPA) values yet reported. Dipolar interactions due to intracellular agglomeration, which are included in the simulated SPA, were found to be the main cause of changes in the magnetic relaxation dynamics of MNPs under in vitro conditions. These results pave the way for the magnetism-based design of MNPs that can retain their heating efficiency in vivo, thereby improving the outcome of clinical hyperthermia experiments

Low-Dimensional Assemblies of Magnetic MnFe2O4 Nanoparticles and Direct In Vitro Measurements of Enhanced Heating Driven by Dipolar Interactions: Implications for Magnetic Hyperthermia

Magnetic fluid hyperthermia (MFH), the procedure of raising the temperature of tumor cells using magnetic nanoparticles (MNPs) as heating agents, has proven successful in treating some types of cancer. However, the low heating power generated under physiological conditions makes it necessary a high local concentration of MNPs at tumor sites. Here, we report how the in vitro heating power of magnetically soft MnFe2O4 nanoparticles can be enhanced by intracellular low-dimensional clusters through a strategy that includes: (a) the design of the MNPs to retain Neel magnetic relaxation in high-viscosity media, and (b) culturing MNP-loaded cells under magnetic fields to produce elongated intracellular agglomerates. Our direct in vitro measurements demonstrated that the specific loss power (SLP) of elongated agglomerates (SLP = 576 +/- 33 W/g) induced by culturing BV2 cells in situ under a dc magnetic field was increased by a factor of 2 compared to the SLP = 305 +/- 25 W/g measured in aggregates freely formed within cells. A numerical mean-field model that included dipolar interactions quantitatively reproduced the SLPs of these clusters both in phantoms and in vitro, suggesting that it captures the relevant mechanisms behind power losses under high-viscosity conditions. These results indicate that in situ assembling of MNPs into low-dimensional structures is a sound possible way to improve the heating performance in MFH

The relevance of Brownian relaxation as power absorption mechanism in Magnetic Hyperthermia

The Linear Response Theory (LRT) is a widely accepted framework to analyze the power absorption of magnetic nanoparticles for magnetic fluid hyperthermia. Its validity is restricted to low applied fields and/or to highly anisotropic magnetic nanoparticles. Here, we present a systematic experimental analysis and numerical calculations of the specific power absorption for highly anisotropic cobalt ferrite (CoFe 2 O 4 ) magnetic nanoparticles with different average sizes and in different viscous media. The predominance of Brownian relaxation as the origin of the magnetic losses in these particles is established, and the changes of the Specific Power Absorption (SPA) with the viscosity of the carrier liquid are consistent with the LRT approximation. The impact of viscosity on SPA is relevant for the design of MNPs to heat the intracellular medium during in vitro and in vivo experiments. The combined numerical and experimental analyses presented here shed light on the underlying mechanisms that make highly anisotropic MNPs unsuitable for magnetic hyperthermia

Tuning Properties of Iron Oxide Nanoparticles in Aqueous Synthesis without Ligands to Improve MRI Relaxivity and SAR.

Aqueous synthesis without ligands of iron oxide nanoparticles (IONPs) with exceptional properties still remains an open issue, because of the challenge to control simultaneously numerous properties of the IONPs in these rigorous settings. To solve this, it is necessary to correlate the synthesis process with their properties, but this correlation is until now not well understood. Here, we study and correlate the structure, crystallinity, morphology, as well as magnetic, relaxometric and heating properties of IONPs obtained for different durations of the hydrothermal treatment that correspond to the different growth stages of IONPs upon initial co-precipitation in aqueous environment without ligands. We find that their properties were different for IONPs with comparable diameters. Specifically, by controlling the growth of IONPs from primary to secondary particles firstly by colloidal and then also by magnetic interactions, we control their crystallinity from monocrystalline to polycrystalline IONPs, respectively. Surface energy minimization in the aqueous environment along with low temperature treatment is used to favor nearly defect-free IONPs featuring superior properties, such as high saturation magnetization, magnetic volume, surface crystallinity, the transversal magnetic resonance imaging (MRI) relaxivity (up to r₂ = 1189 mM(-1)·s(-1) and r₂/r₁ = 195) and specific absorption rate, SAR (up to 1225.1 W·gFe(-1))

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.

This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de novo myelodysplastic syndrome (MDS) and deletion 5q. Additional chromosomal abnormalities were strongly related to different patients' characteristics. In multivariate analysis, the most important predictors of both OS and AML transformation risk were number of chromosomal abnormalities (P<0.001 for both outcomes), platelet count (P<0.001 and P=0.001, respectively) and proportion of bone marrow blasts (P<0.001 and P=0.016, respectively). The number of chromosomal abnormalities defined three risk categories for AML transformation (del(5q), del(5q)+1 and del(5q)+ ≥ 2 abnormalities) and two for OS (one group: del(5q) and del(5q)+1; and del(5q)+ ≥ 2 abnormalities, as the other one); with a median survival time of 58.0 and 6.8 months, respectively. Platelet count (P=0.001) and age (P=0.034) predicted OS in patients with '5q-syndrome'. This study demonstrates the importance of additional chromosomal abnormalities in MDS patients with deletion 5q, challenges the current '5q-syndrome' definition and constitutes a useful reference series to properly analyze the results of clinical trials in these patients